🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chifeng
Clinical trial register · China

Clinical Trials in Chifeng, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca9 China Medical University, China2 Xuanwu Hospital, Beijing2 Chifeng Tumor Hospital2 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.1
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chifeng

29 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury
NCT07733401Spinal Cord Injury, Acute Spinal Cord Injury (SCI)
Xuanwu Hospital, Beijing
Not applicable
80
Beijing, Guangzhou, Maoming, Cangzhou, Shijiazhuang, Chifeng, Dezhou, Jinan
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Baoding, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu, Chifeng
2026-08-24
Recruiting
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
NCT07711262Seasonal Allergic Rhinitis
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Phase 3
550
Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Baotou, Chifeng, Yinchuan, Jinan
2026-08-18
Recruiting
Polypills Approach for Multiple Cardiovascular Risk Factors
NCT07679828Hypertension, Dyslipidemia, Diabetes
China Medical University, China
Not applicable
8,252
Zhengzhou, Chifeng, Tongliao, Kunshan, Suzhou, Taizhou, Jinzhou, Panjin
2026-07-11
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894Gastroesophageal Reflux Disease, Emotional Distress
Xinghua Liu
Not applicable
500
Beijing, Baiyin, Shenzhen, Guiyang, Xingtai, Xinle, Chifeng, Hohhot
2026-06-29
Not yet open
Study on Efficacy and Safety of VMAT Technique With Local Dose Escalation for Unresectable Pancreatic Cancer
NCT07242911Ppancreatic Cancer
Chifeng Tumor Hospital
Observational
30
Chifeng
2026-01-01
Recruiting
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
NCT06909773Cardiovascular Diseases
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Recruiting
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
NCT07220538Ischemic Stroke Hospitalized, Impairment, Cognitive
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Beipiao, Benxi, Chenzhou, Chifeng, Dalian
2025-11-28
Not yet open
Dosimetric Differences and Clinical Significance Analysis Between Body Gamma Knife and VMAT Radiotherapy for Primary Liver Cance
NCT07211815Primary Liver Cancers
Chifeng Tumor Hospital
Observational
30
Chifeng
2025-11-01
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
NCT07187687Intracerebral Hemorrhage
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
By invitation
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT07023965Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans
Beijing Northland Biotech. Co., Ltd.
Observational
542
Beijing, Chifeng, Dalian, Hangzhou, Xi'an
2025-06-30
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Wuhan, Chifeng, Suzhou, Beijing, Chengdu
2025-02-10
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Luoyang, Changsha, Chifeng
2024-12-19
Active, closed
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
NCT06646419COPD
AstraZeneca
Observational
1,368
Anyang, Baise City, Beijing, Bijie, Changsha, Chenzhou, Chifeng, Chuzhou
2024-11-13
Recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
POASAC Study (Preoperative Anemia Severity and Classification Study)
NCT06499974Anemia
Peking Union Medical College Hospital
Observational
1,000
Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot
2024-08-02
Recruiting
Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia
NCT06359106Oxygenation Index
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx
Phase 2
229
Beijing, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Guanzhou, Guiyang
2020-09-18
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chifeng

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Chifeng.

How many clinical trials are recruiting in Chifeng?

20 of the 29 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chifeng), 29 studies
PhaseStudiesRecruitingShare
Phase 3131144.8%
Not applicable5417.2%
Observational5117.2%
Phase 2206.9%
Phase 4226.9%
Phase 1/2113.4%
Phase 2/3113.4%

Most active sponsors

Lead sponsors with the most studies (Chifeng)
Lead sponsorStudiesRecruiting
AstraZeneca98
Chifeng Tumor Hospital20
China Medical University, China22
Xuanwu Hospital, Beijing21
argenx10
Beijing Northland Biotech. Co., Ltd.10
Betta Pharmaceuticals Co., Ltd.11
Boehringer Ingelheim11
Cytokinetics11
Dianthus Therapeutics11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.